Company Overview
By using the body’s immune system, Anixa Biosciences is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.
Recent News
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Stock Overview
Symbol
ANIX
Exchange
Nasdaq
Market Cap
108.53m
Last Price
$3.19
52-Week Range
$2.32 - $5.4566
07/14/2026 08:00 PM EDT
Investor Relations
Mike Catelani
President, COO & CFO
T: 408-708-9808